Gyre Therapeutics is trading at $5.86, down 5.02% during the October 21, 2026 session; no clearly reported company-specific announcement explaining the decline surfaced in the search.
- Recent coverage noted H.C. Wainwright reiterated its Buy rating and $18 target; this does not establish a reason for the session’s decline.
- Biotech was rising while Gyre was falling, and available evidence does not establish a sector or broad-market explanation.